OC-0647 Analysis of biomarkers for late radiotherapy toxicity in the REQUITE project

Published on Apr 1, 2019in Radiotherapy and Oncology4.856
· DOI :10.1016/S0167-8140(19)31067-9
Christopher J. Talbot21
Estimated H-index: 21
,
David Azria56
Estimated H-index: 56
+ 20 AuthorsCatharine M L West77
Estimated H-index: 77
Sources
Abstract
References0
Newest
Cited By1
Newest
#1Carmen Bergom (MCW: Medical College of Wisconsin)H-Index: 14
#2Catharine M L West (NIHR: National Institute for Health Research)H-Index: 77
Last. Wendy A. Woodward (University of Texas MD Anderson Cancer Center)H-Index: 66
view all 19 authors...
Abstract Purpose and Methods The advent of affordable and rapid next-generation DNA sequencing technology, along with the US Supreme Court ruling invalidating gene patents, has led to a deluge of germline and tumor genetic variant tests that are being rapidly incorporated into clinical cancer decision making. A major concern for clinicians is whether the presence of germline mutations may increase the risk of radiation toxicity or secondary malignancies. Since minimal clinical data exist to info...
20 CitationsSource